Cover Image

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Fabrizio Martora,1 Claudio Marasca,2 Sara Cacciapuoti,1 Federica Fariello,1 Luca Potestio,1 Teresa Battista,1 Massimiliano Scalvenzi,1 Matteo Megna1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Dermatology Unit, Medical Depa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Martora F (Author), Marasca C (Author), Cacciapuoti S (Author), Fariello F (Author), Potestio L (Author), Battista T (Author), Scalvenzi M (Author), Megna M (Author)
Format:	Book
Published:	Dove Medical Press, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023)

Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report
by: Martora F, et al.
Published: (2024)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023)

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
by: Martora F, et al.
Published: (2024)

Real-Life Experience of Secukinumab in Patients With Hidradenitis Suppurativa
by: F.J. Melgosa Ramos, et al.
Published: (2023)

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
by: Megna M, et al.
Published: (2024)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023)

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab
by: Ryan C. Saal, BS, et al.
Published: (2023)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
by: Aikaterini Kyriakou, et al.
Published: (2018)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
by: Ian Gorovoy, et al.
Published: (2009)

Effectiveness of secukinumab for overlapping hidradenitis suppurativa and ankylosing spondylitis
by: Mariam AlAfeefi, et al.
Published: (2024)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
by: Battista T, et al.
Published: (2023)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
by: Potestio L, et al.
Published: (2023)

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
by: Fabrizio Martora, MD, et al.
Published: (2022)

A complication in a patient with hidradenitis suppurativa taking adalimumab
by: Olivia D. Perez, BA, et al.
Published: (2022)

Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa
by: Sarah Alnaif, BHSc, et al.
Published: (2023)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
by: Fotiadou C, et al.
Published: (2016)

Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience
by: Andrea Chiricozzi, et al.
Published: (2020)

Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa
by: Astrid-Helene Ravn Jørgensen, et al.
Published: (2018)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022)

Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment
by: Soichiro Ikeya, et al.
Published: (2021)

Adalimumab Experience in the Management of Hidradenitis Suppurativa Burdened with Rapp-Hodgkin Syndrome
by: Nikolay N. Murashkin, et al.
Published: (2023)

Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab
by: Anna Schuch, et al.
Published: (2017)

Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study
by: Sofía Haselgruber, et al.
Published: (2024)

Metastatic squamous cell carcinoma in a patient treated with adalimumab for hidradenitis suppurativa
by: Rachel Giesey, BA, et al.
Published: (2017)

Adalimumab for the Treatment of Periodontitis in a 35-Year-Old Woman with Hidradenitis Suppurativa
by: Yiqiu Yao, et al.
Published: (2023)

Hidradenitis Suppurativa: Modern Concepts of Pathogenesis and Therapy; Successful Experience of Adalimumab Therapy
by: M. M. Khobeish, et al.
Published: (2018)

Adalimumab effect on pain in hidradenitis suppurativa patients: systematic review and meta-analysis
by: Aikaterini Tsentemeidou, et al.
Published: (2022)

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis
by: Maryam Shayesteh Alam, MD, FRCPC, FAAD, et al.
Published: (2020)

Adalimumab in the treatment of moderate-severe hidradenitis suppurativa: a cost-effectiveness analysis
by: Sofia Borges, et al.
Published: (2018)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
by: Megna M, et al.
Published: (2023)

Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal
by: José Miguel Neves, et al.
Published: (2022)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023)

[Artículo Traducido] Secukinumab en hidradenitis supurativa, experiencia en practica clínica real
by: F.J. Melgosa Ramos, et al.
Published: (2023)

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment
by: Napolitano M, et al.
Published: (2017)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
by: Potestio L, et al.
Published: (2023)

Vulvar cancer in hidradenitis suppurativa
by: T.F.M. Vergeldt, et al.
Published: (2022)

L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]
by: Potestio L, et al.
Published: (2024)

Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review
by: Potestio L, et al.
Published: (2024)

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
by: Martora F, et al.
Published: (2022)